ondansetron has been researched along with Heart Defects, Congenital in 5 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 8.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "Two cohort studies, including more than 2500 pregnant women exposed to ondansetron in early pregnancy, have raised concerns over an increased risk of congenital heart defects." | 7.83 | Ondansetron and pregnancy: possible congenital heart defects. ( , 2016) |
| "Ondansetron is an effective antiemetic that is being widely used as a second-line treatment option for severe nausea and vomiting of pregnancy in accordance with clinical guidelines." | 4.02 | Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC). ( Cassina, M; Damkier, P; Diav-Citrin, O; Kaplan, YC; Shechtman, S; Weber-Schoendorfer, C, 2021) |
| "Evidence for the fetal safety of ondansetron, a 5-HT3 receptor antagonist that is commonly prescribed for nausea and vomiting during pregnancy, is limited and conflicting." | 3.88 | Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. ( Bateman, BT; Desai, RJ; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Straub, L; Zhu, Y, 2018) |
| "Two cohort studies, including more than 2500 pregnant women exposed to ondansetron in early pregnancy, have raised concerns over an increased risk of congenital heart defects." | 3.83 | Ondansetron and pregnancy: possible congenital heart defects. ( , 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huybrechts, KF | 2 |
| Hernandez-Diaz, S | 2 |
| Straub, L | 2 |
| Gray, KJ | 2 |
| Zhu, Y | 2 |
| Mogun, H | 2 |
| Bateman, BT | 2 |
| Damkier, P | 1 |
| Kaplan, YC | 1 |
| Shechtman, S | 1 |
| Diav-Citrin, O | 1 |
| Cassina, M | 1 |
| Weber-Schoendorfer, C | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Koren, G | 1 |
5 other studies available for ondansetron and Heart Defects, Congenital
| Article | Year |
|---|---|
Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antiemetics; Cleft Lip; Cleft Palate; Fema | 2020 |
Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC).
Topics: Antiemetics; Cleft Lip; Cleft Palate; Contraindications, Drug; Drug Labeling; European Union; Female | 2021 |
Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cleft Lip; Cleft Palate; Female; Heart Defects, Con | 2018 |
Treating morning sickness in the United States--changes in prescribing are needed.
Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Approval; Drug Combinations; Female; Heart Defects, Conge | 2014 |
Ondansetron and pregnancy: possible congenital heart defects.
Topics: Female; Heart Defects, Congenital; Humans; Ondansetron; Pregnancy; Serotonin 5-HT3 Receptor Antagoni | 2016 |